Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Lynne B. Parshall received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.08 per share and expire on June 23, 2036. Following this grant, she holds 28,000 options directly. According to the terms, the option vests in full on the first anniversary of the grant date, assuming she continues to serve on the board of directors.

Insights

Equity compensation analyst

Routine director option grant adds equity incentive without signaling market view.

Director Lynne B. Parshall received 28,000 stock options for Foghorn Therapeutics common stock at an exercise price of $4.08 per share, expiring on June 23, 2036. This is characterized as a grant or award acquisition, not an open-market purchase.

The options vest in full on the first anniversary of the grant date, conditioned on continued board service. That structure is typical for non-employee director compensation, aligning incentives with longer-term company performance.

Because this is a compensatory grant rather than a discretionary buy or sale, it carries limited signaling value about the director’s view of the stock. Future filings may show how often such awards are granted and whether additional equity grants change the overall scale of director compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PARSHALL B LYNNE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct)

Footnotes (1)

1. F1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Post-grant option holdings: 28,000 options +2 more

5 metrics

Options granted 28,000 options Stock options for Foghorn Therapeutics common stock

Exercise price $4.08 per share Option strike price for the grant

Post-grant option holdings 28,000 options Total options held following this transaction

Option expiration date June 23, 2036 Final date to exercise granted options

Vesting schedule 100% after 1 year Vests on first anniversary of grant with continued board service

Key Terms

Stock Options (Right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date regulatory

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The option vests in full on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did Lynne B. Parshall receive in this FHTX Form 4 filing?

Lynne B. Parshall received a grant of stock options for 28,000 shares of Foghorn Therapeutics common stock. These options are a form of equity compensation rather than an open-market stock purchase or sale.

What is the exercise price of the new Foghorn Therapeutics (FHTX) options?

The granted stock options have an exercise price of $4.08 per share. This means Parshall can buy Foghorn Therapeutics common stock at $4.08 if she exercises the options after they vest and before they expire.

When do Lynne B. Parshall’s FHTX stock options vest?

The option vests in full on the first anniversary of the grant date. Vesting is conditioned on Parshall’s continued service on Foghorn Therapeutics’ board of directors through that one-year period.

When do the Foghorn Therapeutics (FHTX) director options expire?

The stock options granted to Lynne B. Parshall expire on June 23, 2036. After that expiration date, any unexercised options will no longer be exercisable for Foghorn Therapeutics common stock.

How many FHTX options does Lynne B. Parshall hold after this transaction?

After this grant, Parshall holds 28,000 stock options directly. The filing does not show additional derivative positions, so this grant represents her reported option holdings in this Form 4.

Is this FHTX Form 4 a stock purchase or sale by the director?

No, the Form 4 reports a grant or award acquisition of stock options, coded as “A.” It reflects equity compensation, not an open-market buy or sell of Foghorn Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:01 PM Accepted by SEC EDGAR 06/25/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for B. Lynne Parshall	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)